Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 901–1,000 of 1,000
RANK/RANK-Ligand/OPG: Ein neuer Therapieansatz in der Osteoporosebehandlung
Preisinger, E. (2007) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 6
Seeman, E. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0350-z · Cited by 3
Monoclonal Gammopathy of Undetermined Significance
Minisola, S., Pepe, J., & Romagnoli, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070145 · Cited by 3
Biochemical bone markers and biological effects of osteoporosis therapy
Kovačev-Zavišić, B., Novaković-Paro, J., Djuric, N., Ičin, T., Todorovic-Djilas, L., & Kovacev, N. (2012) · Vojnosanitetski pregled · doi:10.2298/vsp1205432k · Cited by 2
KAMEO, Y., Imai, K., Yuki, M. I. Y. A., Kim, Y. K., & ADACHI, T. (2025) · Biomedical Engineering Advances · doi:10.1016/j.bea.2025.100176 · Cited by 2
Choi, S., Park, S., Jung, J. A., Baek, S., & Lim, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1631034 · Cited by 2
Okada, A., Baba, R., Ishibashi, Y., Otagaki, Y., Kodama, T., Egusa, G., Nagano, G., Matsuda, T., Hattori, N., & Ohno, H. (2025) · Medicine · doi:10.1097/md.0000000000044882 · Cited by 2
Social Impact of Osteoporotic Fractures
Muratore, M., Conversano, F., Renna, M. D., Pisani, P., Villani, V., & Casciaro, S. (2014) · International Journal on Measurement Technologies and Instrumentation Engineering · doi:10.4018/ijmtie.2014040104 · Cited by 2
Li, L., Xu, J., Ji, H., Xia, S., & Shi, F. (2026) · Medicine · doi:10.1097/md.0000000000047150 · Cited by 2
Lassoued, H., Lamy, O., Francioli, C., & Rodríguez, E. G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1761311 · Cited by 2
Lu, K., Wang, S., & Yang, S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70270 · Cited by 2
Risk of Therapeutic Failure due to Ineffectiveness of Medication
Woring, V. E. (2011) · NASA STI Repository (National Aeronautics and Space Administration) · Cited by 4
Denosumab--a new option in the treatment of osteoporosis.
Franek, E. (2011) · PubMed · Cited by 2
Therapeutic Options in the Prevention and Treatment of Postmenopausal Osteoporosis
Kamel, H. K., O’Connell, M. B., & Gold, D. T. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.s6-a.1 · Cited by 2
Basic of Osteoporosis and the Topics
Kawaguchi, H. (2015) · Spinal Surgery · doi:10.2531/spinalsurg.29.259 · Cited by 2
Republished: Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency
Daga, N., & Joseph, F. (2021) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2021.234508rep · Cited by 2
Posttransplantation bone disease: prevalence, surveillance, prevention, and management
Duncan, C. (2021) · Wiley eBooks · doi:10.1002/9781119612780.ch30 · Cited by 2
Effects of Digestive Diseases on Bone Metabolism
Sylvester, F. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-67293-1.00091-8 · Cited by 2
The potential of RANKL reverse signaling as a novel pharmacological target
Honma, M. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22145 · Cited by 2
Human Macrophage- and Osteoclast-Based Constructs Do Not Induce Ectopic Bone Formation
Husch, J. F. A., Coquelin, L., Chevallier, N., van Dijk, N. W. M., Leeuwenburgh, S. C. G., & van den Beucken, J. J. J. P. (2023) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-023-00315-z · Cited by 2
Campisi, G. (2024) · Dental Cadmos · doi:10.19256/d.cadmos.02.2024.04 · Cited by 2
Yang, J. W., Park, Y., Lee, J. J., Kwok, S., Ju, J. H., Kim, W., & Park, S. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2024-001438 · Cited by 2
Kultima, K., Ashtiani, S. H., Erngren, I., Khoonsari, P. E., Carlsson, H., Herman, S., Freyhult, E., Mallmin, H., & Hailer, N. P. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf091 · Cited by 2
Singh, M., Sabharwal, S., Jamwal, N., Gupta, M., & Garg, K. (2025) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_108_25 · Cited by 2
New directions in osteoporosis therapy: Intravenous ibandronate and denosumab
Teng, G. G., Patkar, N. M., & Saag, K. G. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0021-2 · Cited by 2
Osteoporosis: New-Generation Drugs
Resch, H. (2010) · Breast Care · doi:10.1159/000321254 · Cited by 2
Osteoporosis inducida por glucocorticoides: ¿qué hay de nuevo?
Acín, M. P. A. (2007) · Reumatología Clínica · doi:10.1016/s1699-258x(07)73624-0 · Cited by 5
ESCI award lecture: from a little mouse to rationale medicine for bone loss
Leibbrandt, A., & Penninger, J. M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02215.x · Cited by 2
Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal?
Lattouf, J., & Fred Saad, C. (2010) · Current Oncology · doi:10.3747/co.v17i0.723 · Cited by 2
Osteoclasts: Essentials and Methods
Rucci, N., & Teti, A. M. (2017) · Learning materials in biosciences · doi:10.1007/978-3-319-58955-8_3 · Cited by 3
Francis, R. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6231-8.10069-8 · Cited by 2
Blair, H. C., Simonet, W. S., Lacey, D. L., & Zaidi, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50008-1 · Cited by 2
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
Zhang, N., Williams, B. R., Lü, P., An, Z., & Chin, C. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch31 · Cited by 2
Immunogenicity Assessment of Antibody Therapeutics
Stas, P., Pletinckx, J., Gansemans, Y., & Lasters, I. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511596773.005 · Cited by 2
Cada, D. J., Levien, T. L., & Baker, D. E. (2010) · Hospital Pharmacy · doi:10.1310/hpj4510-785 · Cited by 2
Animal models of osteoporosis and development of anti-osteoporotic agents
Azuma, Y. (2007) · Folia Pharmacologica Japonica · doi:10.1254/fpj.130.201 · Cited by 3
Osteoporosis. Problema clínico de actualidad
Cruz, J. G., Martínez, R. F., Pérez, R. R., Nadal, E. D. S., & Deses, C. D. D. L. (2008) · Anales Médicos de la Asociación Médica del Centro Médico ABC · Cited by 2
La inhibición del RANKL en el tratamiento de la osteoporosis: denosumab
Pérez-Edo, L. (2011) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2010.11.003 · Cited by 5
Böcker, W., Radic, T., Schönitzer, V., Haasters, F., Mutschler, W., & Schieker, M. (2011) · Gene · doi:10.1016/j.gene.2011.08.008 · Cited by 2
Grande, D. A., Shah, N. V., Catanzano, A. A., Nelson, F. R. T., Hoey, D. A., & Jacobs, C. R. (2011) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-201101000-00007 · Cited by 2
Denosumab for behandling av postmenopausal osteoporose
Syversen, U., Halse, J., Geisler, J., & Eriksen, E. F. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.10.1116 · Cited by 2
Fast, D., Chandra, A., Lin, Y., Murray, M., & Gellenbeck, K. W. (2012) · CRC Press eBooks · doi:10.1201/b12893-6 · Cited by 2
Bone Drugs in Pediatrics: Efficacy and Challenges
Klein, G. L. (2014) · Springer eBooks · doi:10.1007/978-1-4899-7436-5 · Cited by 2
How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders
Langdahl, B. L., & Ralston, S. H. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3316 · Cited by 2
Osteogenesis imperfecta in combination with Graves disease
Шеремета, М. С., Pigarova, E. A., Сергеевна, К. К., Михайловна, Б. И., Tyulpakov, A. N., & Rumyantsev, P. O. (2017) · Obesity and metabolism · doi:10.14341/omet2017477-82 · Cited by 2
Kamimura, M., Taguchi, A., Nakamura, Y., Koiwai, H., Ikegami, S., Uchiyama, S., & Kato, H. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s154686 · Cited by 2
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch37 · Cited by 4
Biological characteristics of osteoporosis drugs: the effect of osteoblast–osteoclast coupling
Kim, S., Moon, S. J., & Seo, J. T. (2019) · International Journal of Oral Biology · doi:10.11620/ijob.2019.44.1.1 · Cited by 2
Goldenberg, N., & Kumagai, A. K. (2008) · Elsevier eBooks · doi:10.1016/b978-141603000-3.10009-7 · Cited by 2
Denosumab for the treatment of osteoporosis
McClung, M. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00075-7 · Cited by 2
Self-citationMcClung, M. R. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch50 · Cited by 3
Self-citationGold, D. T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00082-0 · Cited by 2
Gifre, L., Vidal, J., Carrasco, J. L., Muxí, Á., Portell, E., Monegal, A., Guañabens, N., & Peris, P. (2022) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2022000200005 · Cited by 2
Post-craniopharyngioma surgery hypocalcemia due to denosumab use for osteoporosis: A case report
Jia, L., Hu, Y., & Gui-lan, J. (2024) · Medicine · doi:10.1097/md.0000000000039649 · Cited by 2
Fricke, U., & Schwabe, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_2 · Cited by 2
Reaction network analysis in biochemical signaling pathways
Martínez‐Forero, I., Peláez, A. I., & Villoslada, P. (2011) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · Cited by 2
Information for rational drug prescribing to older patients : Availability and applicability
Beers, E. (2014) · Utrecht University Repository (Utrecht University) · Cited by 2
OSTEOCLASTOGENESIS AND BONE DISEASES
Mikán, J., & Oliveros, W. (2007) · Revista Med · Cited by 9
Development of Novel Models for Studying Osteoclasts
Thudium, C. S. (2014) · Lund University Publications (Lund University) · Cited by 4
Neue pathophysiologische Stoffwechselwege in der Osteoporose: Zukünftige innovative Therapieansätze?
Neumann, E. (2006) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-006-0086-8 · Cited by 4
Denosumab: do we need another of the same?
Ahmed, I. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12036 · Cited by 2
Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)
Terpos, E., Christoulas, D., & Dimopoulos, M. A. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.11.1265 · Cited by 2
Is denosumab better than alendronate in the treatment of osteoporosis?
Lewiecki, E. M. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0981 · Cited by 2
Self-citationIs denosumab a safe and effective treatment for postmenopausal osteoporosis?
Ackerman, K. E. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0845 · Cited by 2
Current, new and emerging anti-resorptive drugs; antibody blockade of RANKL action
Martin, T. J. (2006) · BoneKEy-Osteovision · doi:10.1138/20060214 · Cited by 2
Metabolic Bone Disorders of the Spine
Unnanuntana, A., Miki, R. A., Gladnick, B. P., Sherman, P. J., Madore, G. R., & Lane, J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6726-9.00087-0 · Cited by 2
Campisi, G., Mauceri, R., Bertoldo, F., Fusco, V., & Bedogni, A. (2020) · doi:10.32388/d95owg · Cited by 2
Lane, J. M., & Serota, A. C. (2006) · Current Opinion in Orthopedics · doi:10.1097/01.bco.0000244038.32542.31 · Cited by 2
Postoperative Bone Mineral Health Optimization in the Geriatric Patient
Kondapalli, A. V., & Walker, M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-78969-5_11 · Cited by 1
Riesco-Bárcena, C., Cortés, J. I., Grau-García, E., González-Puig, L., Leal, S., Huaylla, A., & Román‐Ivorra, J. A. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.07.020 · Cited by 1
Cho, Y. R., Byun, S., & Lee, H.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-28252-7 · Cited by 2
Advances in Osteoporosis: Pathophysiology, therapies and herbal insights
Nema, R. K., Kujur, A., Dansena, J., Yadav, V., Tandan, D., & Tripathi, V. (2026) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.18304.1771325345 · Cited by 1
Supronik, J., Giorgadze, E., Blicharski, T., Sánchez‐Vidaurre, S., Díaz, L. P., Paravisini, A., & Millán, S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030291 · Cited by 1
Current outlook on the use of monoclonal antibody therapies for osteoporosis
Almohaya, M. S., Almehthel, M. S., & Kendler, D. L. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2641051 · Cited by 1
Masri, D., Rosenfeld, E., Adut, S., Chaushu, G., Tsvetov, G., Avishai, G., Ghanaiem, O., Jonas, E., Zlotogorski‐Hurvitz, A., & Muchnik, D. (2026) · JBMR Plus · doi:10.1093/jbmrpl/ziag038 · Cited by 1
Bartosik, M., Wolf, E., Simon, A., Schmidt, F. N., Windels, O., Klostermeier, U. C., Barvencik, F., Amling, M., & Oheim, R. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101918 · Cited by 1
Normocalcemic Primary Hyperparathyroidism: An Evolving Understanding
Kalik, S., Abate, E. G., & Cusano, N. E. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.016 · Cited by 1
Wang, Y., Wang, X., Yu, G., Zhang, L., Xue, C., Gong, W., Luo, J., Lu, C., & Wang, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1886136 · Cited by 2
Moseley, K. F., & de Beur, S. M. J. (2010) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-374271-1.00059-9 · Cited by 1
Biotechnological advances in monoclonal antibody therapy: the RANK ligand inhibitor antibody
Kiss, E. V., Kuluncsics, Z., Kiss, Z., & Poór, G. (2010) · Orvosi Hetilap · doi:10.1556/oh.2010.29010 · Cited by 1
Tratamiento de las osteoporosis
Henríquez, M. S., & Hernández, D. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)73245-x · Cited by 1
Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics
Tabrizi, M. A., & Funelas, C. B. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_13 · Cited by 1
Denosumab for the treatment and prevention of postmenopausal osteoporosis
Bennett, T. G., Marshall, K. L., Khan, F., Wark, J. D., & Brand, C. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010011 · Cited by 1
Retracted(2009) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34078-6 · Cited by 1
Antibody and Other Immune-Based Therapies for Myeloma
Munshi, N. C., & Tai, Y. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_12 · Cited by 1
Pharmacogenomics of Osteoporosis-Related Bone Fractures
Venegas, K. R., Aguilera, M. C. A., Cañadas‐Garre, M., & Hernández, M. Á. C. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_29 · Cited by 2
Future Therapies of Osteoporosis
Ng, K. W., & Martin, T. J. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch56 · Cited by 1
Bonnick, S. L., & Lewis, L. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3625-6_9 · Cited by 2
Therapeutic Antibodies from XenoMouse Transgenic Mice
Jakobovits, A. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511596773.010 · Cited by 2
Development and pharmacological effects of anti-RANKL monoclonal antibody drug Denosumab
Takami, M. (2013) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.36.162 · Cited by 2
Quarterly Intravenous Ibandronate for Postmenopausal Osteoporosis
Emkey, R. D. (2008) · Women s Health · doi:10.2217/17455057.4.3.219 · Cited by 2
Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Yang, R., & Liu, S. (2008) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/187221409787002958 · Cited by 1
McCarthy, E. F., & Frassica, F. J. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139946247.005 · Cited by 2
Presente y futuro de los anticuerpos monoclonales en el tratamiento de la osteoporosis
Aresté, J. F. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.04.003 · Cited by 1
Delalande, D., Jung, C., Labedan, I., Lechevalier, P., Madre, C., Roche, S., & Koné‐Paut, I. (2008) · Archives de Pédiatrie · doi:10.1016/j.arcped.2007.11.011 · Cited by 4
Denosumab for the Treatment of Postmenopausal Women at Increased Risk of Osteoporotic Fractures
Bogado, C. E. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6173 · Cited by 1
New Pharmacotherapies in the Treatment of Advanced Prostate Cancer
El-Ayass, W., El-Amm, J., Jain, M. M., & Aragon‐Ching, J. B. (2010) · Clinical Medicine Insights Urology · doi:10.4137/cmu.s5075 · Cited by 1
Clinical Significance of HIV-Associated Bone Loss: When and How to Intervene
Yin, M. T., Shane, E. J., & Anastos, K. (2008) · Future HIV Therapy · doi:10.2217/17469600.2.5.465 · Cited by 1
New drugs for osteoporosis therapy: a review of the clinical trials phase 2 and 3
Tadić, I., Tasić, L., Stupar, N. V., Ilić, K., & Stevanović, D. (2013) · AFMN Biomedicine · doi:10.2478/afmnai-2014-0003 · Cited by 1
Chu, C., Yeh, K., Lee, R., Chen, I., Yu, T., Liu, K., Peng, C.-H., Wang, J., & Wu, W. (2015) · Tzu Chi Medical Journal · doi:10.1016/j.tcmj.2015.08.001 · Cited by 1
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.